Almirall SA ((GB:0O9B)), Almirall ((DE:E2Z)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Almirall S.A. has completed a Phase 3 clinical study titled A Phase 3, Multicentre, Randomised, Double-blind, Vehicle-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Tirbanibulin 10 mg/g Ointment Applied to a Treatment Field Larger Than 25 cm^2 and up to 100 cm^2 in Adult Patients With Actinic Keratosis. The study aimed to assess the efficacy and safety of tirbanibulin ointment in treating actinic keratosis, a common skin condition.
The study tested the application of tirbanibulin, an experimental drug, compared to a vehicle ointment as a placebo. Participants applied the ointment daily for five days, with evaluations for efficacy and safety conducted at multiple intervals.
The study was designed as a randomized, double-blind, parallel-group trial with a primary treatment purpose. Both participants and investigators were blinded to the treatment allocation to ensure unbiased results.
Key dates for the study include its start on December 21, 2023, and the last update on July 27, 2025. These dates are crucial for tracking the study’s progress and ensuring timely data availability.
The completion of this study may influence Almirall’s stock performance positively, as successful results could enhance the market potential of tirbanibulin. Investors may view this development favorably, especially in comparison to competitors in the dermatology sector.
The study is now completed, with further details available on the ClinicalTrials portal.